462 related articles for article (PubMed ID: 33743237)
1. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; van den Berg B; Doets AY; Leonhard SE; Verboon C; Huizinga R; Drenthen J; Arends S; Budde IK; Kleyweg RP; Kuitwaard K; van der Meulen MFG; Samijn JPA; Vermeij FH; Kuks JBM; van Dijk GW; Wirtz PW; Eftimov F; van der Kooi AJ; Garssen MPJ; Gijsbers CJ; de Rijk MC; Visser LH; Blom RJ; Linssen WHJP; van der Kooi EL; Verschuuren JJGM; van Koningsveld R; Dieks RJG; Gilhuis HJ; Jellema K; van der Ree TC; Bienfait HME; Faber CG; Lovenich H; van Engelen BGM; Groen RJ; Merkies ISJ; van Oosten BW; van der Pol WL; van der Meulen WDM; Badrising UA; Stevens M; Breukelman AJ; Zwetsloot CP; van der Graaff MM; Wohlgemuth M; Hughes RAC; Cornblath DR; van Doorn PA;
Lancet Neurol; 2021 Apr; 20(4):275-283. PubMed ID: 33743237
[TBL] [Abstract][Full Text] [Related]
2. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
[TBL] [Abstract][Full Text] [Related]
3. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327
[TBL] [Abstract][Full Text] [Related]
5. Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome.
van Tilburg SJ; Teunissen CE; Maas CCHM; Thomma RCM; Walgaard C; Heijst H; Huizinga R; van Doorn PA; Jacobs BC
EBioMedicine; 2024 Apr; 102():105072. PubMed ID: 38518653
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.
Misawa S; Kuwabara S; Sato Y; Yamaguchi N; Nagashima K; Katayama K; Sekiguchi Y; Iwai Y; Amino H; Suichi T; Yokota T; Nishida Y; Kanouchi T; Kohara N; Kawamoto M; Ishii J; Kuwahara M; Suzuki H; Hirata K; Kokubun N; Masuda R; Kaneko J; Yabe I; Sasaki H; Kaida KI; Takazaki H; Suzuki N; Suzuki S; Nodera H; Matsui N; Tsuji S; Koike H; Yamasaki R; Kusunoki S;
Lancet Neurol; 2018 Jun; 17(6):519-529. PubMed ID: 29685815
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Raphaël JC; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2001; (2):CD002063. PubMed ID: 11406030
[TBL] [Abstract][Full Text] [Related]
8. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
van Koningsveld R; Schmitz PI; Meché FG; Visser LH; Meulstee J; van Doorn PA;
Lancet; 2004 Jan; 363(9404):192-6. PubMed ID: 14738791
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2010 Jun; (6):CD002063. PubMed ID: 20556755
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids for treating Guillain-Barré syndrome.
Hughes RA; van Der Meché FG
Cochrane Database Syst Rev; 2000; (3):CD001446. PubMed ID: 10908498
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroids for treating Guillain-Barré syndrome.
Hughes RA; van der Meché FG
Cochrane Database Syst Rev; 2000; (2):CD001446. PubMed ID: 10796795
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Raphaël JC; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2006 Jan; (1):CD002063. PubMed ID: 16437439
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Raphaël JC; Swan AV; Doorn PA
Cochrane Database Syst Rev; 2004; (1):CD002063. PubMed ID: 14973982
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.
Pritchard J; Hughes RA; Hadden RD; Brassington R
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008630. PubMed ID: 27846348
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroids for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Koningsveld R; van Doorn PA
Cochrane Database Syst Rev; 2006 Apr; (2):CD001446. PubMed ID: 16625544
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.
Rajabally YA
Neurotherapeutics; 2022 Apr; 19(3):885-896. PubMed ID: 35648286
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
Prado MB; Adiao KJB; Turalde CWR; Dasig DA
Acta Neurol Belg; 2024 Mar; ():. PubMed ID: 38553651
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.
Hughes RA; Pritchard J; Hadden RD
Cochrane Database Syst Rev; 2013 Feb; (2):CD008630. PubMed ID: 23450584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
